Truist Financial restated their buy rating on shares of Adverum Biotechnologies (NASDAQ:ADVM – Free Report) in a research report released on Tuesday, Benzinga reports. They currently have a $6.00 price target on the biotechnology company’s stock. Other equities analysts have also issued research reports about the stock. StockNews.com initiated coverage on shares of Adverum Biotechnologies […]